Meridian Bioscience

Meridian Bioscience Assets per Share

The Total Assets per Share of Meridian Bioscience (VIVO) as of Sep 27, 2026 is 10.44 USD. In the previous year, Total Assets per Share was 10.13 USD — a change of 2.97% (higher).

Assets per Share

10.44USD

YoY

2.97%

Last updated:

Total Assets per Share of Meridian Bioscience is 2026 10.44 USD. Total Assets per Share of Meridian Bioscience was 2025 10.13 USD. It decreases by 2.97% higher compared to the previous year.

The Meridian Bioscience Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2015
4.13 USD
Jan 1, 2016
5.68 USD
Jan 1, 2017
5.63 USD
Jan 1, 2018
5.67 USD
Jan 1, 2019
7.34 USD
Jan 1, 2020
9.13 USD
Jan 1, 2021
10.13 USD
Jan 1, 2022
10.44 USD
The Meridian Bioscience Assets per Share history
YEARAssets per ShareYoY
10.44USD+2.97%
10.13USD+10.96%
9.13USD+24.52%
7.34USD+29.47%
5.67USD+0.64%
5.63USD-0.87%
5.68USD+37.48%
4.13USD+3.62%
3.99USD—
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Total Assets per Share of Meridian Bioscience is 10.44 USD in 2026.

Total Assets per Share of Meridian Bioscience changed from 10.13 USD to 10.44 USD, representing a 2.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

Other — Meridian Bioscience

All Key Metrics — Meridian Bioscience